Lateral Flow Immunoassay with Quantum-Dot-Embedded Silica Nanoparticles for Prostate-Specific Antigen Detection

Area of Science:

• Biotechnology
• Nanotechnology
• Medical Diagnostics

Background:

• Prostate cancer diagnosis relies on detecting prostate-specific antigen (PSA).
• Lateral flow immunoassays (LFIA) offer cost-effective, rapid PSA detection.
• Quantum dots (QDs) enhance LFIA sensitivity due to their bright fluorescence.

Purpose of the Study:

• To develop a highly sensitive LFIA kit for prostate cancer detection.
• To utilize QD-embedded silica nanoparticles for improved assay performance.
• To enable prostate cancer diagnosis using simple smartphone-based analysis.

Main Methods:

• Development of a novel LFIA kit incorporating QD-embedded silica nanoparticles.
• Utilizing a smartphone and ImageJ software for signal detection and analysis.
• Testing the kit with human serum samples to evaluate PSA detection and specificity.

Main Results:

• The developed LFIA system achieved a low limit of PSA detection (0.138 ng/mL).
• The system demonstrated high specificity, detecting only PSA and not other proteins.
• Fluorescence signal stability was maintained for 10 days, indicating robustness.

Conclusions:

• The QD-enhanced LFIA kit provides a highly sensitive and convenient method for prostate cancer diagnosis.
• The system's reliance on smartphone technology makes it accessible for widespread use.
• This approach offers a promising tool for early prostate cancer screening and management.